Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertaconazole 2% cream in atopic dermatitis
NCT01792713Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2013
- Primary completion
- Sep 2013
- Countries
- 1
- Sponsor
- Spirig Pharma
- Modality
- Small Molecules
- Conditions
- atopic dermatitis (AD)
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Sertaconazole 2% cream with Placebo (2 arms). Primary endpoint: Change in Patient Global Assessment at 28 days. Started Feb 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Sertaconazole 2% cream
Sertaconazole 2% cream applied twice daily
Placebo
Placebo cream applied twice daily
03
Who it enrols
Adult patients with mild to moderate atopic dermatitis (SCORAD <= 40) with lesions on arms, legs, or neck.
04
Endpoints
Primary
Change in Patient Global Assessment
Secondary
Change in Eczema Area and Severity Index
Change in Dermatology Life Quality Index
Change in Patient Benefit Index
Beyond the preview
Go deeper on NCT01792713.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01792713.